Topical treatment of psoriasis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 12, 2010, Pages 1999-2009

  Laws, Philip M ^a   Young, Helen S ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Psoriasis; Severity; Topical therapy; Treatment

Indexed keywords

AMCINONIDE; ANTIPSORIASIS AGENT; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CALCITRIOL; CLOBETASOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID DERIVATIVE; DESOXIMETASONE; DITHRANOL; EMOLLIENT AGENT; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUTICASONE PROPIONATE; HALCINONIDE; HYDROCORTISONE 17 BUTYRATE 21 PROPIONATE; KERATOLYTIC AGENT; PIMECROLIMUS; PLACEBO; RETINOID DERIVATIVE; TACALCITOL; TACROLIMUS; TAZAROTENE; ULOBETASOL PROPIONATE; UNINDEXED DRUG; VITAMIN D DERIVATIVE; DERMATOLOGICAL AGENT;

ABNORMAL SENSATION; ACNE; AVASCULAR NECROSIS; BANDAGE; CALCIUM HOMEOSTASIS; CATARACT; CHRONIC DISEASE; CLINICAL ASSESSMENT TOOL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTACT DERMATITIS; CUSHING SYNDROME; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; ENDOCRINE DISEASE; ERYTHEMA; FOLLICULITIS; GLAUCOMA; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; HYPERTENSION; HYPOTHALAMIC PITUITARY ADRENAL SUPPRESSION; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MYCOSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SATISFACTION; PERIORAL DERMATITIS; PHOTOTHERAPY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PURPURA; QUALITY OF LIFE; REMISSION; REVIEW; ROSACEA; SKIN ABRASION; SKIN ATROPHY; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN MANIFESTATION; SKIN STINGING SENSATION; STRIAE DISTENSAE; TACHYPHYLAXIS; TELANGIECTASIA; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; PATIENT SELECTION; PRACTICE GUIDELINE; RISK ASSESSMENT; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; DERMATOLOGIC AGENTS; HUMANS; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 77954782436     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.492778     Document Type: Review

References (82)

1. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-271
2. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-456
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol 2009;60:643-659
4. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-147
5. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-850
6. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-407
7. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2009;2:CD005028
8. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl 2):65-8; discussion 9-73
9. Gribetz C, Ling M, Lebwohl M, et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004;51:731-738
10. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-244
11. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-850 (Pubitemid 351509656)
12. van de Kerkhof PC, Barker J, Griffiths CE, et al. Psoriasis: consensus on topical therapies. J Eur Acad Dermatol Venereol 2008;22:859-870
13. Kirby B, Fortune DG, Bhushan M, et al. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000;142:728-732
14. Richards HL, Fortune DG, O'Sullivan TM, et al. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-583
15. Feldman SR, Gelfand JM, Stein Gold L, Jones SD. The role of topical therapy for patients with extensive psoriasis. Cutis 2007;79(Suppl 2):18-31
16. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004;140:408-414
17. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999;107:595-605
18. Long CC, Finlay AY. The finger-tip unit - a new practical measure. Clin Exp Dermatol 1991;16:444-447
19. Volden G, Kragballe K, Van De Kerkhof PC, et al. Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing versus twice daily treatment with clobetasol propionate alone. J Dermatolog Treat 2001;12:141-144
20. Nast A, Kopp IB, Augustin M, et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007;5(Suppl 3):1-119
21. Rang HP, Dale MM. Rang and Dale's pharmacology. 6th edition. Churchill Livingstone, Edinburgh; 2007
22. Cornell RC, Stoughton RB. Correlation of the vasoconstriction assay and clinical activity in psoriasis. Arch Dermatol 1985;121:63-67
23. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272-284
24. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975;111:581-583
25. Feldman SR. Tachyphylaxis to topical corticosteroids: the more you use them, the less they work? Clin Dermatol 2006;24:229-30; discussion 30
26. Katz HI, Hien NT, Prawer SE, et al. Superpotent topical steroid treatment of psoriasis vulgaris - clinical efficacy and adrenal function. J Am Acad Dermatol 1987;16:804-811
27. Chi C-C, Wang S-H, Kirtschig G, Wojnarowska F. Systematic review of the safety of topical corticosteroids in pregnancy. J Am Acad Dermatol 2010;62:694-705
28. Bernhard J, Whitmore C, Guzzo C, et al. Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: report on two double-blind, vehicle-controlled studies. J Am Acad Dermatol 1991;25:1170-1174
29. Olsen EA, Cram DL, Ellis CN, et al. A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991;24:443-447
30. Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003;7:185-192
31. Lebwohl M, Sherer D, Washenik K, et al. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002;41:269-274
32. Ellis CN, Horwitz SN, Menter A. Amcinonide lotion 0.1% in the treatment of patients with psoriasis of the scalp. Curr Ther Res Clin Exp 1988;44:315-324
33. Lepaw MI. Double-blind comparison of halcinonide solution and placebo control in treatment of psoriasis of the scalp. Cutis 1978;21:571-573
34. Savin RC. Desoximetasone - a new topical corticosteroid: short- and long-term experiences. Cutis 1978;21:403-407
35. Franz TJ, Parsell DA, Halualani RM, et al. Betamethasone valerate foam 0.12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999;38:628-632
36. Olsen EA. Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis. Cutis 1996;57(2 Suppl):57-61
37. Stein LF, Sherr A, Solodkina G, et al. Betamethasone valerate foam for treatment of nonscalp psoriasis. J Cutan Med Surg 2001;5:303-307
38. Sears HW. A double-blind, randomized, placebo-controlled evaluation of the efficacy and safety of hydrocortisone buteprate 0.1% cream in the treatment of psoriasis. Adv Ther 1997;14:140-149
39. Pauporte M, Maibach H, Lowe N, et al. Fluocinolone acetonide topical oil for scalp psoriasis. J Dermatolog Treat 2004;15:360-364
40. Morimoto S, Kumahara Y. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3. Med J Osaka Univ 1985;35:51-54
41. Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J 2003;9:2
42. Ashcroft DM, Po AL, Williams HC, Griffiths CE. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-967
43. Camarasa JM, Ortonne JP, Dubertret L. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 2003;14:8-13
44. Langner A, Stapor W, Ambroziak M. Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland. Br J Dermatol 2001;144(Suppl 58):11-16
45. Gerritsen MJ, Van De Kerkhof PC, Langner A. Long-term safety of topical calcitriol 3 microg g(-1) ointment. Br J Dermatol 2001;144(Suppl 58):17-19
46. van de Kerkhof PC, Berth-Jones J, Griffiths CE, et al. Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis. Br J Dermatol 2002;146:414-422 (Pubitemid 34603813)
47. Baadsgaard O, Traulsen J, Roed-Petersen J, Jakobsen H. Optimal concentration of tacalcitol in once-daily treatment of psoriasis. J Dermatolog Treat 1995;6:145-150
48. Carmelo S. Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis. J Eur Acad Dermatol Venereol 1996;6:142-146
49. Kragballe K. Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903). Arch Dermatol 1989;125:1647-1652
50. Cheer SM, Plosker GL. Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001;2:389-406
51. Lebwohl M, Freeman AK, Chapman MS, et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004;51:723-730
52. Kreuter A, Sommer A, Hyun J, et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006;142:1138-1143
53. Berger TG, Duvic M, Van Voorhees AS, et al. The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol 2006;54:818-823
54. McGill A, Frank A, Emmett N, et al. The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J 2005;19:1012-1014
55. Mason J, Mason A, Cork MJ. Topical preparations for the treatment of psoriasis in primary care: a systematic review. University of York, Centre for Health Economics; 2002
56. Van de Kerkhof PC. Dithranol treatment in psoriasis: after 75 years, still going strong. Eur J Dermatol 1991;1:79-88
57. Ingram JT. The approach to psoriasis. BMJ 1953;2:591-594
58. Jekler J, Swanbeck G. One-minute dithranol therapy in psoriasis: a placebo-controlled paired comparative study. Acta Derm Venereol 1992;72:449-450
59. Grattan C, Hallam F, Whitefield M. A new aqueous dithranol gel for psoriasis: Comparison with placebo and calcipotriol ointment. J Dermatolog Treat 1997;8:11-15
60. Paghdal KV, Schwartz RA. Topical tar: back to the future. J Am Acad Dermatol 2009;61:294-302
61. Goeckerman W. Treatment of psoriasis. Northwest Med 1925;24:229-231
62. Kanzler MH, Gorsulowsky DC. Efficacy of topical 5% liquor carbonis detergens vs. its emollient base in the treatment of psoriasis. Br J Dermatol 1993;129:310-314
63. Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. J Dermatolog Treat 2004;15:14-22
64. Maughan WZ, Muller SA, Perry HO, et al. Incidence of skin cancers in patients with atopic dermatitis treated with ocal tar. A 25-year follow-up study. J Am Acad Dermatol 1980;3:612-615
65. Stern RS, Zierler S, Parrish JA. Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation. Lancet 1980;1:732-735
66. Hannuksela-Svahn A, Pukkala E, Laara E, et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 2000;114:587-590
67. Lam J, Polifka JE, Dohil MA. Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. J Am Acad Dermatol 2008;59:295-315
68. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92
69. Chandraratna RA. Tazarotene: the first receptor-selective topical retinoid for the treatment of psoriasis. J Am Acad Dermatol 1997;37:S12-7
70. Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994;30:581-590
71. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48:760-767
72. Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-711 (Pubitemid 28213714)
73. Veraldi S, Caputo R, Pacifico A, et al. Short contact therapy with tazarotene in psoriasis vulgaris. Dermatology 2006;212:235-237
74. Koo JY, Lowe NJ, Lew-Kaya DA, et al. Tazarotene plus UVB phototherapy in the treatment of psoriasis. J Am Acad Dermatol 2000;43:821-828
75. Lebwohl M. The role of salicylic acid in the treatment of psoriasis. Int J Dermatol 1999;38:16-24
76. Hagemann I, Proksch E. Topical treatment by urea reduces epidermal hyperproliferation and induces differentiation in psoriasis. Acta Derm Venereol 1996;76:353-356
77. Guenther L, Van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-323
78. Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-393
79. Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54
80. Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004;209:308-313
81. Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/ Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-1160
82. van de Kerkhof PC, Hoffmann V, Anstey A, et al. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009;160:170-176